Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance

Shares were down 15% at 12:11 p.m. London time, shortly after the announcement (7:12 a.m. ET). The company said the lower outlook was driven by weaker second-half U.S. sales growth forecasts for its Wegovy weight loss drug and Ozempic diabetes treatment. "For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than- expected market expansion and competition," it added in a statement. This is a developing story. Please check back for updates. Medical bottles and a syr ...